



ASX ANNOUNCEMENT

15 FEBRUARY 2022

**CHIMERIC SIGNS SPONSORED RESEARCH AGREEMENT WITH  
UNIVERSITY OF PENNSYLVANIA (SUPPLEMENTARY ANNOUNCEMENT)**

Further to the announcement of the sponsored research agreement with University of Pennsylvania ("Penn") released on 1 February 2022, at the request of the ASX, Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and an Australian leader in cell therapy, provides additional information regarding the agreement with Penn.

The research will be led by one of the inventors of CHM 2101, Xianxin Hua, MD, PhD. Dr Hua is a professor of Cancer Biology in Penn's Perelman School of Medicine, and an investigator at the Abramson Family Cancer Research Institute.

The research will focus on furthering the development of CHM 2101 with preclinical studies in gastrointestinal cancers, enhancing the understanding of CHM 2101 through correlative studies and investigating CDH17 directed follow on candidates. The research complements and is consistent with the Company's announcement on 28 July 2021 of receiving the exclusive license for CDH17.

As part of the agreement, Chimeric has the first right of negotiation to license Penn intellectual property arising from the conduct of the sponsored research.

Under the agreement, Chimeric will reimburse Penn's expenditure on the research. Whilst the cost to Chimeric of the agreement is not considered financially material in the context of Chimeric's annual budgeted expenditure, the nature of the agreement is considered market sensitive. The cost of the agreement is expected to be funded from existing cash reserves. There are no conditions precedent, and the agreement is effective immediately. The agreement is subject to usual industry termination provisions.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.



## ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)